Switch theme
Sign up to access all valuation multiples
China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2024, the medical distribution business accounts for 82.8% of its total revenue. CR Pharma’s manufacturing business, 18.0% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.
2007
73.0K+
LTM Revenue $38.6B
LTM EBITDA $2.3B
$7.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CR Pharmaceutical has a last 12-month revenue of $38.6B and a last 12-month EBITDA of $2.3B.
In the most recent fiscal year, CR Pharmaceutical achieved revenue of $31.5B and an EBITDA of $2.0B.
CR Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CR Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $28.9B | $31.5B | XXX | XXX | XXX |
| Gross Profit | $3.7B | $4.4B | XXX | XXX | XXX |
| Gross Margin | 13% | 14% | XXX | XXX | XXX |
| EBITDA | $1.8B | $2.0B | XXX | XXX | XXX |
| EBITDA Margin | 6% | 6% | XXX | XXX | XXX |
| Net Profit | $396M | $471M | XXX | XXX | XXX |
| Net Margin | 1% | 1% | XXX | XXX | XXX |
| Net Debt | $3.9B | $3.8B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, CR Pharmaceutical's stock price is HKD 5 (or $1).
CR Pharmaceutical has current market cap of HKD 31.5B (or $4.1B), and EV of HKD 57.5B (or $7.4B).
See CR Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.4B | $4.1B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, CR Pharmaceutical has market cap of $4.1B and EV of $7.4B.
CR Pharmaceutical's trades at 0.2x LTM EV/Revenue multiple, and 3.5x LTM EBITDA.
Analysts estimate CR Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CR Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $7.4B | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | 3.7x | XXX | XXX | XXX |
| P/E | 8.2x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | 4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCR Pharmaceutical's NTM/LTM revenue growth is 6%
CR Pharmaceutical's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $41K for the same period.
Over next 12 months, CR Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CR Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CR Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 12% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $41K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 10% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CR Pharmaceutical acquired XXX companies to date.
Last acquisition by CR Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . CR Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CR Pharmaceutical founded? | CR Pharmaceutical was founded in 2007. |
| Where is CR Pharmaceutical headquartered? | CR Pharmaceutical is headquartered in Hong Kong. |
| How many employees does CR Pharmaceutical have? | As of today, CR Pharmaceutical has 73.0K+ employees. |
| Who is the CEO of CR Pharmaceutical? | CR Pharmaceutical's CEO is Mr. Xiaosong Bai. |
| Is CR Pharmaceutical publicy listed? | Yes, CR Pharmaceutical is a public company listed on HKG. |
| What is the stock symbol of CR Pharmaceutical? | CR Pharmaceutical trades under 03320 ticker. |
| When did CR Pharmaceutical go public? | CR Pharmaceutical went public in 2016. |
| Who are competitors of CR Pharmaceutical? | Similar companies to CR Pharmaceutical include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of CR Pharmaceutical? | CR Pharmaceutical's current market cap is $4.1B |
| What is the current revenue of CR Pharmaceutical? | CR Pharmaceutical's last 12-month revenue is $38.6B. |
| What is the current EBITDA of CR Pharmaceutical? | CR Pharmaceutical's last 12-month EBITDA is $2.3B. |
| What is the current EV/Revenue multiple of CR Pharmaceutical? | Current revenue multiple of CR Pharmaceutical is 0.2x. |
| What is the current EV/EBITDA multiple of CR Pharmaceutical? | Current EBITDA multiple of CR Pharmaceutical is 3.5x. |
| What is the current revenue growth of CR Pharmaceutical? | CR Pharmaceutical revenue growth between 2023 and 2024 was 9%. |
| Is CR Pharmaceutical profitable? | Yes, CR Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
